Keros Therapeutics, Inc. (KROS) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 9 Buy, 7 Hold.
The consensus price target is $102.60 (low: $96.00, high: $107.00), representing an upside of 788.3% from the current price $11.55.
Analysts estimate Earnings Per Share (EPS) of $-5.19 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.00 vs est $-5.19 (beat +3.6%). 2025: actual $2.34 vs est $2.30 (beat +1.8%). Analyst accuracy: 97%.
KROS Stock — 12-Month Price Forecast
$102.60
▲ +788.31% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Keros Therapeutics, Inc., the average price target is $102.60, with a high forecast of $107.00, and a low forecast of $96.00.
The average price target represents a +788.31% change from the last price of $11.55.
Highest Price Target
$107.00
Average Price Target
$102.60
Lowest Price Target
$96.00
KROS Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Keros Therapeutics, Inc. in the past 3 months
EPS Estimates — KROS
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$5.00
vs Est –$5.19
▲ 3.8% off
2025
Actual $2.34
vs Est $2.30
▲ 1.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — KROS
57%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.004B
vs Est $0.001B
▲ 84.4% off
2025
Actual $0.244B
vs Est $0.246B
▼ 0.8% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
